ONVO - オ―ガノボ・ホ―ルディングス （Organovo Holdings Inc.） オ―ガノボ・ホ―ルディングスONVOのチャート
ONVOの企業情報
| symbol | ONVO |
|---|---|
| 会社名 | Organovo Holdings Inc （オ―ガノボ・ホ―ルディングス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 オルガノボ・ホールディングス(Organovo Holdings Inc.)は機能的なヒト組織の開発・商業化を主とする初期の商業的段階の企業である。同社は主に、プラットフォーム技術を利用して3次元（3D）で人間の組織構築物を作る。同社は主に製品の開発を行う。その製品は、予測毒性学、吸収、分布、代謝、排泄（ADME）、薬物代謝および薬物動態（DMPK）における応用を含む薬物効果の前臨床評価に使用される3Dヒト組織、創薬・開発用の人間の生物学または疾患の生きた動的モデルとしてのカスタマイズされたヒト組織、並びにバイパス移植用の血管、神経損傷修復用の神経移植片、および損傷した組織および器官の修復または交換のための機能的組織パッチなどの臨床用途の三次元ヒト組織を含む。 オ―ガノボ・ホ―ルディングスは米国のバイオテクノロジ―企業。人間の組織や器官を3Dバイオプリンティング技術により生成し、変質またはダメ―ジを受けたヒト細胞の治療の研究開発・商業化に従事。生きた細胞のバイオインクと適合性のあるハイドロゲルを利用する同社技術の3Dバイオプリンタ―「ノボジェン」を開発。本社はカリフォルニア州サンディエゴ。 organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice. |
| 本社所在地 | 6275 Nancy Ridge Drive Suite 110 San Diego CA 92121 USA |
| 代表者氏名 | Taylor J. Crouch テイラーJ.クラウチ |
| 代表者役職名 | President Chief Executive Officer |
| 電話番号 | +1 858-224-1000 |
| 設立年月日 | 40148 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 75人 |
| url | www.organovo.com |
| nasdaq_url | https://www.nasdaq.com/symbol/onvo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -31.41940 |
| 終値（lastsale） | 1.12 |
| 時価総額（marketcap） | 127063270.88 |
| 時価総額 | 時価総額（百万ドル） 123.65980 |
| 売上高 | 売上高（百万ドル） 4.30200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 84.04680 |
| 当期純利益 | 当期純利益（百万ドル） -32.11700 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 30 June 2018 Organovo Holdings Inc revenues decreased 30% to $689K. Net loss decreased 27% to $7.4M. Revenues reflect Products and services decrease of 42% to $546K Collaborations and licenses decrease of 7% to $43K. Lower net loss reflects Research and development expenses - Bala decrease of 32% to $3.2M (expense) Stock-based Compensation in SGA. decrease of 37% to $1.1M (expense) selling. |
ONVOのテクニカル分析
ONVOのニュース
Griping stocks: Cronos Group Inc. (NASDAQ:CRON -1.53%), Organovo Holdings, Inc. (NASDAQ:ONVO -2.14%) 2023/03/11 17:11:13 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Griping stocks: Cronos Group Inc. (NASDAQ:CRON -1.53%), Organovo Holdings, Inc. (NASDAQ:ONVO -2.14%) appeared first on Stocks Equity .
3D Bioprinting Market to Reach $3.3 Billion by 2027, Fueled by Growing Demand for Organ and Tissue Replacement Technologies 2023/03/02 18:57:00 SBWire
BICO Group AB (US) and 3D Systems, Inc. (US) are the Top Players in the 3D Bioprinting Market Northbrook, IL 60062 -- ( SBWIRE ) -- 03/02/2023 -- The 3D bioprinting industry is set to revolutionize medical science and the way we treat diseases and illnesses in the near future. By using 3D bioprinting technology, scientists and researchers can create living tissue and organs on demand and in a precise manner, allowing for more precise and accurate treatments for various diseases. This technology also has the potential to revolutionize drug discovery and testing, as well as the development of personalized medicines. 3D bioprinting could also be used to create affordable prosthetics and implants for patients, as well as organ replacements for those in need of a transplant. As the technology advances, more applications are certain to become available, opening up a vast array of possibilities for the industry. 3D Bioprinting market in terms of revenue was estimated to be worth $1.3 billion in 2022 and is poised to reach $3.3 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027 according to a latest report published by MarketsandMarkets™.
Morning Stocks Trending Alert: Organovo Holdings, Inc. (NASDAQ:ONVO), Camber Energy, Inc. (AMEX:CEI) 2023/02/23 16:26:26 Stock Equity
ONVO has seen its SMA50 which is now 60.81%. In looking the SMA 200 we see that the stock has seen a 36.11%. CEI has seen its SMA50 which is … The post Morning Stocks Trending Alert: Organovo Holdings, Inc. (NASDAQ:ONVO), Camber Energy, Inc. (AMEX:CEI) appeared first on Stocks Equity .
Let’s Dive Into The Organovo Holdings Inc. (NASDAQ: ONVO) Stock Forecast. 2023/02/20 20:00:00 Marketing Sentinel
In the last trading session, 0.44 million Organovo Holdings Inc. (NASDAQ:ONVO) shares changed hands as the company’s beta touched 0.99. With the company’s per share price at $2.88 changed hands at -$0.32 or -10.00% during last session, the market valuation stood at $30.61M. ONVO’s last price was a discount, traded about -62.15% off its 52-week … Let’s Dive Into The Organovo Holdings Inc. (NASDAQ: ONVO) Stock Forecast. Read More »
Weird But Effective stocks: Organovo Holdings, Inc. (NASDAQ:ONVO -10.00%), Ra Medical Systems, Inc. (AMEX:RMED -3.37%) 2023/02/18 11:54:04 Stock Equity
ONVO has seen its SMA50 which is now 67.31%. In looking the SMA 200 we see that the stock has seen a 35.31%. RMED has seen its SMA50 which is … The post Weird But Effective stocks: Organovo Holdings, Inc. (NASDAQ:ONVO -10.00%), Ra Medical Systems, Inc. (AMEX:RMED -3.37%) appeared first on Stocks Equity .
Griping stocks: Cronos Group Inc. (NASDAQ:CRON -1.53%), Organovo Holdings, Inc. (NASDAQ:ONVO -2.14%) 2023/03/11 17:11:13 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Griping stocks: Cronos Group Inc. (NASDAQ:CRON -1.53%), Organovo Holdings, Inc. (NASDAQ:ONVO -2.14%) appeared first on Stocks Equity .
3D Bioprinting Market to Reach $3.3 Billion by 2027, Fueled by Growing Demand for Organ and Tissue Replacement Technologies 2023/03/02 18:57:00 SBWire
BICO Group AB (US) and 3D Systems, Inc. (US) are the Top Players in the 3D Bioprinting Market Northbrook, IL 60062 -- ( SBWIRE ) -- 03/02/2023 -- The 3D bioprinting industry is set to revolutionize medical science and the way we treat diseases and illnesses in the near future. By using 3D bioprinting technology, scientists and researchers can create living tissue and organs on demand and in a precise manner, allowing for more precise and accurate treatments for various diseases. This technology also has the potential to revolutionize drug discovery and testing, as well as the development of personalized medicines. 3D bioprinting could also be used to create affordable prosthetics and implants for patients, as well as organ replacements for those in need of a transplant. As the technology advances, more applications are certain to become available, opening up a vast array of possibilities for the industry. 3D Bioprinting market in terms of revenue was estimated to be worth $1.3 billion in 2022 and is poised to reach $3.3 billion by 2027, growing at a CAGR of 9.6% from 2022 to 2027 according to a latest report published by MarketsandMarkets™.
Morning Stocks Trending Alert: Organovo Holdings, Inc. (NASDAQ:ONVO), Camber Energy, Inc. (AMEX:CEI) 2023/02/23 16:26:26 Stock Equity
ONVO has seen its SMA50 which is now 60.81%. In looking the SMA 200 we see that the stock has seen a 36.11%. CEI has seen its SMA50 which is … The post Morning Stocks Trending Alert: Organovo Holdings, Inc. (NASDAQ:ONVO), Camber Energy, Inc. (AMEX:CEI) appeared first on Stocks Equity .
Let’s Dive Into The Organovo Holdings Inc. (NASDAQ: ONVO) Stock Forecast. 2023/02/20 20:00:00 Marketing Sentinel
In the last trading session, 0.44 million Organovo Holdings Inc. (NASDAQ:ONVO) shares changed hands as the company’s beta touched 0.99. With the company’s per share price at $2.88 changed hands at -$0.32 or -10.00% during last session, the market valuation stood at $30.61M. ONVO’s last price was a discount, traded about -62.15% off its 52-week … Let’s Dive Into The Organovo Holdings Inc. (NASDAQ: ONVO) Stock Forecast. Read More »
Weird But Effective stocks: Organovo Holdings, Inc. (NASDAQ:ONVO -10.00%), Ra Medical Systems, Inc. (AMEX:RMED -3.37%) 2023/02/18 11:54:04 Stock Equity
ONVO has seen its SMA50 which is now 67.31%. In looking the SMA 200 we see that the stock has seen a 35.31%. RMED has seen its SMA50 which is … The post Weird But Effective stocks: Organovo Holdings, Inc. (NASDAQ:ONVO -10.00%), Ra Medical Systems, Inc. (AMEX:RMED -3.37%) appeared first on Stocks Equity .
Why Organovo Holdings, Inc. Stock Soared 49.7% This Week 2022/03/04 03:13:39 The Motley Fool
The company''s licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
Organovo, BICO reach licensing deal on bioprinting patents 2022/02/23 14:14:58 Seeking Alpha
Organovo (ONVO) and BICO reached agreement on a broad license for BICO and its affiliate companies to Organovos foundational patent portfolio in 3D bioprinting.Organovo and BICO
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents 2022/02/23 13:05:00 Benzinga
SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO ), and BICO today announced they have reached agreement on a broad license for BICO and its affiliate companies to Organovo''s foundational patent portfolio in 3D bioprinting. Founded in 2016, BICO (formerly Cellink) is the leading bio convergence company in the world. Cellink continues to operate as a wholly owned division of BICO. Organovo exclusively licensed early bioprinting work by Gabor Forgacs, its scientific founder, and Thomas Boland of Clemson, both bioprinting pioneers. After its founding, the company did early innovation in the 3D bioprinter space and obtained a further broad set of patents that provide foundational claims in the bioprinting space. In order to broaden the impact of the technology and serve the needs of a broad array of researchers and other users of bioprinting, the company seeks to make these patents available for license to first rate bioprinter developers. Organovo Executive Chairman Keith Murphy commented, "Organovo celebrates the success of CELLINK''s bioprinting product lines in opening up the horizons of 3D
Organovo Welcomes New Sr. Vice President of Strategy and Business Development 2022/02/18 18:00:00 Organovo Holdings
SAN DIEGO , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using 3D bioprinting technology, today announced the hiring of Curtis Tyree , PhD, as Sr.
Global 4D Printing In Healthcare Market: Emerging Trends, Major Key Players 3D Systems, Inc and Organovo Holdings Inc 2021/12/23 13:49:23 OpenPR
According to the report, The global 4D Printing in the Healthcare market size is expected to reach $50.76 Billion by 2028 growing at the CAGR of 27.71% from 2021 to 2028. The major driver for the 4D printing industry in